Journal of Molecular and Cellular Cardiology
Volume 48, Issue 6 , Pages 1215-1224 , June 2010

Derivation and characterization of human fetal MSCs: An alternative cell source for large-scale production of cardioprotective microparticles

  • Ruenn Chai Lai

      Affiliations

    • Institute of Medical Biology, Agency for Science Technology and Research (A⁎STAR), Singapore
    • National University of Singapore Graduate School of Integrative Sciences and Engineering, Singapore
    • ,
  • Fatih Arslan

      Affiliations

    • Laboratory of Experimental Cardiology, University Medical Center Utrecht, the Netherlands
    • ,
  • Soon Sim Tan

      Affiliations

    • Institute of Medical Biology, Agency for Science Technology and Research (A⁎STAR), Singapore
    • ,
  • Betty Tan

      Affiliations

    • Bioinformatics Institute, A⁎STAR, Singapore
    • ,
  • Andre Choo

      Affiliations

    • Bioprocessing Technology Institute, A⁎STAR, Singapore
    • ,
  • May May Lee

      Affiliations

    • Bioprocessing Technology Institute, A⁎STAR, Singapore
    • ,
  • Tian Sheng Chen

      Affiliations

    • Institute of Medical Biology, Agency for Science Technology and Research (A⁎STAR), Singapore
    • ,
  • Bao Ju Teh

      Affiliations

    • Institute of Medical Biology, Agency for Science Technology and Research (A⁎STAR), Singapore
    • ,
  • John Kun Long Eng

      Affiliations

    • Nanyang Technological University, Singapore
    • ,
  • Harwin Sidik

      Affiliations

    • Institute of Medical Biology, Agency for Science Technology and Research (A⁎STAR), Singapore
    • ,
  • Vivek Tanavde

      Affiliations

    • Bioinformatics Institute, A⁎STAR, Singapore
    • ,
  • Wei Sek Hwang

      Affiliations

    • Department of Laboratory Medicine (Histopathology), KK Women's and Children's Hospital, Singapore
    • ,
  • Chuen Neng Lee

      Affiliations

    • Department of Surgery, NUS, Singapore
    • ,
  • Reida Menshawe El Oakley

      Affiliations

    • Department of Surgery, NUS, Singapore
    • ,
  • Gerard Pasterkamp

      Affiliations

    • Laboratory of Experimental Cardiology, University Medical Center Utrecht, the Netherlands
    • ,
  • Dominique P.V. de Kleijn

      Affiliations

    • Laboratory of Experimental Cardiology, University Medical Center Utrecht, the Netherlands
    • Interuniversity Cardiology Institute of the Netherlands, Utrecht, the Netherlands
    • ,
  • Kok Hian Tan

      Affiliations

    • Department of Maternal Fetal Medicine, KK Women's and Children's Hospital, Singapore
    • ,
  • Sai Kiang Lim

      Affiliations

    • Institute of Medical Biology, Agency for Science Technology and Research (A⁎STAR), Singapore
    • Department of Surgery, NUS, Singapore
    • Corresponding Author InformationCorresponding author. Institute of Medical Biology, 8A Biomedical Grove, #05-05 Immunos, Singapore 138648. Tel.: +65 6407 0150; fax: +65 6464 2048.

Received 11 September 2009 ,Revised 15 December 2009 ,Accepted 28 December 2009.

References 

  1. Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy. 2005;7:36–45
  2. Minguell JJ, Erices A. Mesenchymal stem cells and the treatment of cardiac disease. Exp. Biol. Med. (Maywood). 2006;231:39–49
  3. Schuleri KH, Boyle AJ, Hare JM. Mesenchymal stem cells for cardiac regenerative therapy. Handb. Exp. Pharmacol. 2007;195–218
  4. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch. Intern. Med. 2007;167:989–997
  5. Mazhari R, Hare JM. Advances in cell-based therapy for structural heart disease. Prog. Cardiovasc. Dis. 2007;49:387–395
  6. Ohnishi S, Nagaya N. Prepare cells to repair the heart: mesenchymal stem cells for the treatment of heart failure. Am. J. Nephrol. 2007;27:301–307
  7. Behfar A, Terzic A. Optimizing adult mesenchymal stem cells for heart repair. J. Mol. Cell Cardiol. 2007;42:283–284
  8. Atsma DE, Fibbe WE, Rabelink TJ. Opportunities and challenges for mesenchymal stem cell-mediated heart repair. Curr. Opin. Lipidol. 2007;18:645–649
  9. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat. Med. 2005;11:367–368
  10. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J. Cell Biochem. 2006;98:1076–1084
  11. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation. 2004;109:1543–1549
  12. Leedham SJ, Brittan M, McDonald SA, Wright NA. Intestinal stem cells. J Cell Mol Med. 2005;9:11–24
  13. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am. J. Physiol. Renal Physiol. 2005;289:F31–F42
  14. Patschan D, Plotkin M, Goligorsky MS. Therapeutic use of stem and endothelial progenitor cells in acute renal injury: ca ira. Curr. Opin. Pharmacol. 2006;6:176–183
  15. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat. Med. 2006;12:459–465
  16. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006;20:661–669
  17. Mayer H, Bertram H, Lindenmaier W, Korff T, Weber H, Weich H. Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation. J. Cell Biochem. 2005;95:827–839
  18. Nakagami H, Maeda K, Morishita R, Iguchi S, Nishikawa T, Takami Y, et al. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler. Thromb. Vasc. Biol. 2005;25:2542–2547
  19. Van Overstraeten-Schlogel N, Beguin Y, Gothot A. Role of stromal-derived factor-1 in the hematopoietic-supporting activity of human mesenchymal stem cells. Eur. J. Haematol. 2006;76:488–493
  20. Cheng L, Qasba P, Vanguri P, Thiede MA. Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells. J. Cell Physiol. 2000;184:58–69
  21. Lian Q, Lye E, Suan Yeo K, Khia Way Tan E, Salto-Tellez M, Liu TM, et al. Derivation of clinically compliant MSCs from CD105+, CD24− differentiated human ESCs. Stem Cells. 2007;25:425–436
  22. Sze SK, de Kleijn DP, Lai RC, Khia Way Tan E, Zhao H, Yeo KS, et al. Elucidating the secretion proteome of human embryonic stem cell-derived mesenchymal stem cells. Mol. Cell Proteomics. 2007;6:1680–1689
  23. Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L, et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation. 2010;121:80–90
  24. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009;9:581–593
  25. Ethical, legal and social issues in human stem cell research, reproductive and therapeutic cloning. Singapore Bioethics Advisory Committee Report 2002.
  26. Wege H, Chui MS, Le HT, Tran JM, Zern MA. SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity. Nucleic Acids Res. 2003;31:E3
  27. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–317
  28. Tsai MS, Lee JL, Chang YJ, Hwang SM. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum. Reprod. 2004;19:1450–1456
  29. Guillot PV, Gotherstrom C, Chan J, Kurata H, Fisk NM. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells. 2007;25:646–654
  30. Peng HH, Wang TH, Chao AS, Chang SD. Isolation and differentiation of human mesenchymal stem cells obtained from second trimester amniotic fluid; experiments at Chang Gung Memorial Hospital. Chang Gung Med. J. 2007;30:402–407
  31. Roubelakis MG, Pappa KI, Bitsika V, Zagoura D, Vlahou A, Papadaki HA, et al. Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev. 2007;16:931–952
  32. Yen ML, Chien CC, Chiu IM, Huang HI, Chen YC, Hu HI, et al. Multilineage differentiation and characterization of the human fetal osteoblastic 1.19 cell line: a possible in vitro model of human mesenchymal progenitors. Stem Cells. 2007;25:125–131
  33. Jo CH, Kim OS, Park EY, Kim BJ, Lee JH, Kang SB, et al. Fetal mesenchymal stem cells derived from human umbilical cord sustain primitive characteristics during extensive expansion. Cell Tissue Res. 2008;334:423–433
  34. Kermani AJ, Fathi F, Mowla SJ. Characterization and genetic manipulation of human umbilical cord vein mesenchymal stem cells: potential application in cell-based gene therapy. Rejuvenation Res. 2008;11:379–386
  35. Poloni A, Rosini V, Mondini E, Maurizi G, Mancini S, Discepoli G, et al. Characterization and expansion of mesenchymal progenitor cells from first-trimester chorionic villi of human placenta. Cytotherapy. 2008;10:690–697
  36. Wang XY, Lan Y, He WY, Zhang L, Yao HY, Hou CM, et al. Identification of mesenchymal stem cells in aorta–gonad–mesonephros and yolk sac of human embryos. Blood. 2008;111:2436–2443
  37. Zhang ZY, Teoh SH, Chong MS, Schantz JT, Fisk NM, Choolani MA, et al. Superior osteogenic capacity for bone tissue engineering of fetal compared to perinatal and adult mesenchymal stem cells. Stem Cells. 2009;27:126–137
  38. Tang YL, Zhao Q, Qin X, Shen L, Cheng L, Ge J, et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann. Thorac. Surg. 2005;80:229–236discussion 36-7
  39. Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: paradoxes of passaging. Exp. Hematol. 2004;32:414–425
  40. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int. J. Biochem. Cell Biol. 2004;36:568–584
  41. Majumdar MK, Keane-Moore M, Buyaner D, Hardy WB, Moorman MA, McIntosh KR, et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J. Biomed. Sci. 2003;10:228–241
  42. Meziani F, Tesse A, Andriantsitohaina R. Microparticles are vectors of paradoxical information in vascular cells including the endothelium: role in health and diseases. Pharmacol. Rep. 2008;60:75–84
  43. Redman CW, Sargent IL. Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta. 2008;29(Suppl. A):S73–S77
  44. Zwicker JI. Tissue factor-bearing microparticles and cancer. Semin. Thromb. Hemost. 2008;34:195–198
  45. Aharon A, Brenner B. Microparticles, thrombosis and cancer. Best Pract. Res. Clin. Haematol. 2009;22:61–69
  46. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb. Haemost. 2009;101:439–451
  47. Castellana D, Kunzelmann C, Freyssinet JM. Pathophysiologic significance of procoagulant microvesicles in cancer disease and progression. Hamostaseologie. 2009;29:51–57
  48. Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, Tedgui A. Endothelial microparticles in diseases. Cell Tissue Res. 2009;335:143–151
  49. Horstman LL, Jy W, Bidot CJ, Nordberg ML, Minagar A, Alexander JS, et al. Potential roles of cell-derived microparticles in ischemic brain disease. Neurol. Res. 2009;31:799–806
  50. Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev. 2009;23:225–229
  51. Davizon P, Lopez JA. Microparticles and thrombotic disease. Curr. Opin. Hematol. 2009;16:334–341
  52. Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle. 2009;8:2014–2018
  53. Doeuvre L, Plawinski L, Toti F, Angles-Cano E. Cell-derived microparticles: a new challenge in neuroscience. J. Neurochem. 2009;110:457–468
  54. Sabatier F, Camoin-Jau L, Anfosso F, Sampol J, Dignat-George F. Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence. J. Cell Mol. Med. 2009;13:454–471
  55. Stein E, McMahon B, Kwaan H, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract. Res. Clin. Haematol. 2009;22:153–163
  56. Milsom C, Rak J. Tissue factor and cancer. Pathophysiol. Haemost. Thromb. 2008;36:160–176
  57. Hartvigsen K, Chou MY, Hansen LF, Shaw PX, Tsimikas S, Binder CJ, et al. The role of innate immunity in atherogenesis. J. Lipid Res. 2009;50 Suppl:S388–S393
  58. Benameur T, Andriantsitohaina R, Martinez MC. Therapeutic potential of plasma membrane-derived microparticles. Pharmacol. Rep. 2009;61:49–57
  59. Knight DR. Editorial overview: cardioprotective drugs for myocardial ischemic injury—a therapeutic area at risk. Curr. Opin. Investig. Drugs. 2007;8:190–192

PII: S0022-2828(09)00568-9

doi: 10.1016/j.yjmcc.2009.12.021

Journal of Molecular and Cellular Cardiology
Volume 48, Issue 6 , Pages 1215-1224 , June 2010

Article Tools

* Image Usage & Resolution